Research-use catalog page
COA request, lot visibility, availability, and schema stay aligned.
Ipamorelin is a selective pentapeptide GHRP studied in preclinical models for GH release without cortisol or prolactin elevation — the most selective GHRP in its class.
Temporarily unavailable
This product is listed in the catalog, but it is not currently available for ordering. Pricing, specifications, and support details remain visible while launch availability is being finalized.
Free shipping on orders over $150
Research Supplies
Need bacteriostatic water, syringes, or an alcohol prep kit? Email us — we can bundle reconstitution supplies with your order.
Ask about a research kit →Need the COA before you order? Request it here.
In your order
Lyophilized vial
Sterile-filtered, freeze-dried peptide in glass vial, sealed under inert gas.
Lot ID on every vial
Printed lot ID ties this exact vial to its analytical record.
COA on request
Independent third-party HPLC certificate, matched to your lot, sent on request.
Carrier-tracked shipping
Shipped from a US facility with full carrier tracking and protective packaging.
The Peptific standard
Peptide quality is invisible until it isn’t. Lot identity, purity, fill integrity, and chain of custody are the difference between usable research material and wasted budget.
Third-party HPLC tested
Every lot is tested for identity and purity by an independent analytical lab. Certificate of Analysis available on request, tied to the exact lot you receive.
Lyophilized and lot-tracked
Sterile-filtered, freeze-dried, sealed under inert gas. Each vial carries its own lot ID — full chain of custody from fill to delivery.
US-based fulfillment
Orders ship from a temperature-controlled US facility with carrier tracking. No drop-shipping, no opaque overseas relay.
Real support, not a ticket queue
A real person responds to research questions, lot questions, and order questions — usually same business day. No bot triage.
How it works
Ipamorelin acts as a ghrelin receptor (GHS-R1a) agonist, stimulating pulsatile GH release from pituitary somatotropes. Its selectivity profile differentiates it from other GHRPs: in direct comparison studies, it produces robust GH secretion without significant ACTH, cortisol, aldosterone, or prolactin responses, making it the preferred compound for isolated GH-axis research.
Compound profile
Product definition
Ipamorelin is a selective pentapeptide GHRP studied in preclinical models for GH release without cortisol or prolactin elevation — the most selective GHRP in its class.
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide developed as a selective growth hormone secretagogue. It was among the first GHRPs to demonstrate clear selectivity for GH over other pituitary hormones, a property that has made it a reference compound in GH secretagogue research since the late 1990s. In preclinical studies, ipamorelin produces dose-dependent GH pulses with a profile comparable to endogenous GH secretion patterns. Unlike GHRP-2 and GHRP-6, which show significant cortisol and prolactin co-stimulation at effective GH doses, ipamorelin maintains GH specificity — a critical distinction for research protocols examining GH-specific downstream effects on muscle protein synthesis, fat metabolism, or bone density.
Research audience
Ipamorelin is used by researchers studying GH axis pharmacology, GH secretagogue selectivity, acute GH dynamics, bone density mechanisms, and anabolic signaling pathways. It is particularly favored in protocols where GH-specific effects must be isolated from confounding cortisol or prolactin responses.
Research context
Ipamorelin was developed by Novo Nordisk and characterized in the late 1990s as part of the first generation of peptide-based GH secretagogues. The selectivity profile was documented in direct comparison studies with GHRP-2 and GHRP-6 in rats, showing equivalent or superior GH release with dramatically lower stimulation of cortisol and prolactin at comparable doses. The compound has been studied in rodent models for effects on body composition, bone mineral density, and GH-dependent anabolic signaling. Its short half-life of approximately 2 hours makes it suitable for studying acute GH dynamics and pulsatile secretion patterns rather than sustained GH elevation (for which CJC-1295 With DAC is more appropriate). Ipamorelin is frequently used in combination with GHRH analogs (CJC-1295 Without DAC or MOD GRF 1-29) in research protocols examining the synergistic effect of combined GHRH+GHRP administration on GH pulse amplitude — a combination that amplifies GH release more than either compound alone in animal models.
Common questions
You might also want to check out these products.
2X Blend CJC-1295 Without DAC / Ipamorelin
The 2X Blend combines CJC-1295 Without DAC and Ipamorelin — the standard GHRH+GHRP research combination producing synergistic, selective GH pulse amplification through two independent receptor systems.
CJC-1295 Without DAC
CJC-1295 Without DAC (MOD GRF 1-29) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the preferred short-acting GHRH analog for pulsatile GH research protocols, commonly paired with ipamorelin.
CJC-1295 With DAC
$25.00
CJC-1295 With DAC is a long-acting GHRH analog with albumin-binding modification that sustains elevated GH and IGF-1 for 6–8 days per administration in preclinical and early clinical research.
GHRP-6 Acetate
GHRP-6 is a hexapeptide GHS-R1a agonist and the founding GHRP compound — studied in preclinical models for GH release, significant appetite stimulation, and cortisol co-stimulation via ghrelin receptor activation.
IGF-1LR3
$30.00
IGF-1 LR3 is an 83-amino-acid IGF-1 analog with reduced IGFBP binding, extending half-life from ~15 minutes to ~20–30 hours — the most studied long-acting IGF-1 analog in preclinical research.
Hexarelin Acetate
Hexarelin (Examorelin) is the most potent characterized GHRP hexapeptide — GHS-R1a agonist with Phase II human data and unique CD36 cardiac receptor binding providing GH-independent cardioprotection in animal models.
IGF-DES
Tesamorelin
$29.00
Tesamorelin is a 44-amino-acid GHRH analog with N-terminal trans-3-hexenoic acid modification — the only FDA-approved GHRH peptide, validated in Phase III trials for visceral adiposity reduction.
Sermorelin
Sermorelin is a 29-amino-acid synthetic GHRH(1-29) analog — the first FDA-approved GHRH peptide (Geref), with the longest published research history of any synthetic GHRH compound.
MOD GRF 1-29
MOD GRF 1-29 (CJC-1295 Without DAC) is a tetrasubstituted GHRH(1-29) analog with ~30-minute half-life — the most commonly used short-acting GHRH compound for pulsatile GH secretion research.
GHRP-2
GHRP-2 (Pralmorelin) is a synthetic hexapeptide GHS-R1a agonist approved in Japan for GH stimulation testing — a potent non-selective GHRP that stimulates GH alongside cortisol and prolactin.
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy